Effect of Oral Moxifloxacin vs Intravenous Ertapenem Plus Oral Levofloxacin for Treatment of Uncomplicated Acute Appendicitis: The APPAC II Randomized Clinical Trial.
Acute Disease
Administration, Intravenous
Administration, Oral
Adult
Anti-Bacterial Agents
/ administration & dosage
Appendectomy
Appendicitis
/ diagnostic imaging
Drug Therapy, Combination
Ertapenem
/ therapeutic use
Female
Follow-Up Studies
Humans
Levofloxacin
/ therapeutic use
Male
Metronidazole
/ therapeutic use
Middle Aged
Moxifloxacin
/ therapeutic use
Tomography, X-Ray Computed
Young Adult
Journal
JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160
Informations de publication
Date de publication:
26 01 2021
26 01 2021
Historique:
pubmed:
12
1
2021
medline:
11
2
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
Antibiotics are an effective and safe alternative to appendectomy for managing uncomplicated acute appendicitis, but the optimal antibiotic regimen is not known. To compare oral antibiotics with combined intravenous followed by oral antibiotics in the management of computed tomography-confirmed uncomplicated acute appendicitis. The Appendicitis Acuta (APPAC) II multicenter, open-label, noninferiority randomized clinical trial was conducted from April 2017 until November 2018 in 9 Finnish hospitals. A total of 599 patients aged 18 to 60 years with computed tomography-confirmed uncomplicated acute appendicitis were enrolled in the trial. The last date of follow-up was November 29, 2019. Patients randomized to receive oral monotherapy (n = 295) received oral moxifloxacin (400 mg/d) for 7 days. Patients randomized to receive intravenous antibiotics followed by oral antibiotics (n = 288) received intravenous ertapenem (1 g/d) for 2 days followed by oral levofloxacin (500 mg/d) and metronidazole (500 mg 3 times/d) for 5 days. The primary end point was treatment success (≥65%) for both groups, defined as discharge from hospital without surgery and no recurrent appendicitis during 1-year follow-up, and to determine whether oral antibiotics alone were noninferior to intravenous and oral antibiotics, with a margin of 6% for difference. Among 599 patients who were randomized (mean [SD] age, 36 [12] years; 263 [44%] women), 581 (99.7%) were available for the 1-year follow-up. The treatment success rate at 1 year was 70.2% (1-sided 95% CI, 65.8% to ∞) for patients treated with oral antibiotics and 73.8% (1-sided 95% CI, 69.5% to ∞) for patients treated with intravenous followed by oral antibiotics. The difference was -3.6% ([1-sided 95% CI, -9.7% to ∞]; P = .26 for noninferiority), with the confidence limit exceeding the noninferiority margin. Among adults with uncomplicated acute appendicitis, treatment with 7 days of oral moxifloxacin compared with 2 days of intravenous ertapenem followed by 5 days of levofloxacin and metronidazole resulted in treatment success rates greater than 65% in both groups, but failed to demonstrate noninferiority for treatment success of oral antibiotics compared with intravenous followed by oral antibiotics. ClinicalTrials.gov Identifier: NCT03236961; EudraCT Identifier: 2015-003633-10.
Identifiants
pubmed: 33427870
pii: 2775227
doi: 10.1001/jama.2020.23525
pmc: PMC7802006
doi:
Substances chimiques
Anti-Bacterial Agents
0
Metronidazole
140QMO216E
Levofloxacin
6GNT3Y5LMF
Ertapenem
G32F6EID2H
Moxifloxacin
U188XYD42P
Banques de données
ClinicalTrials.gov
['NCT03236961']
Types de publication
Comparative Study
Equivalence Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-362Commentaires et corrections
Type : CommentIn
Références
World J Surg. 2017 Sep;41(9):2411
pubmed: 28050666
World J Surg. 2006 Jun;30(6):1033-7
pubmed: 16736333
Ann Surg. 2019 Dec;270(6):1028-1040
pubmed: 30720508
Br J Surg. 2017 Jan;104(1):52-61
pubmed: 27686365
Colorectal Dis. 2012 Mar;14(3):325-30
pubmed: 21689302
Br J Surg. 2017 Sep;104(10):1355-1361
pubmed: 28677879
BMC Surg. 2018 Dec 17;18(1):117
pubmed: 30558607
Surg Infect (Larchmt). 2010 Feb;11(1):79-109
pubmed: 20163262
Br J Surg. 2019 Oct;106(11):1542-1548
pubmed: 31386199
JAMA. 2015 Jun 16;313(23):2340-8
pubmed: 26080338
J Trauma Acute Care Surg. 2019 Apr;86(4):722-736
pubmed: 30516592
Ann Emerg Med. 2017 Jul;70(1):1-11.e9
pubmed: 27974169
N Engl J Med. 2020 Nov 12;383(20):1907-1919
pubmed: 33017106
J Am Coll Surg. 2014 Aug;219(2):272-9
pubmed: 24951281
JAMA. 2018 Sep 25;320(12):1259-1265
pubmed: 30264120
World J Emerg Surg. 2020 Apr 15;15(1):27
pubmed: 32295644
Br J Surg. 2009 May;96(5):473-81
pubmed: 19358184
JAMA. 2015 Jun 16;313(23):2371-2
pubmed: 26080342
Lancet. 2011 May 7;377(9777):1573-9
pubmed: 21550483
Dis Colon Rectum. 2016 Jun;59(6):529-34
pubmed: 27145310
J Am Coll Surg. 2016 Mar;222(3):309-14
pubmed: 26712246
Br J Surg. 2017 Dec;104(13):1785-1790
pubmed: 28925502
J Trauma Acute Care Surg. 2017 Jun;82(6):1129-1137
pubmed: 28338596
Int J Antimicrob Agents. 2013 Jan;41(1):57-64
pubmed: 23153963
Abdom Radiol (NY). 2021 Mar;46(3):948-959
pubmed: 32914350
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
BMJ Open. 2018 Nov 3;8(11):e023623
pubmed: 30391919
JAMA Surg. 2020 Apr 1;155(4):283-289
pubmed: 32074268
Int J Colorectal Dis. 2015 Sep;30(9):1229-34
pubmed: 25989930
Br J Surg. 2012 Apr;99(4):532-9
pubmed: 22290281
Clin Infect Dis. 2011 Dec;53(11):1074-80
pubmed: 21998288
JAMA. 2020 Aug 11;324(6):581-593
pubmed: 32730561
Br J Surg. 2021 Jun 22;108(6):717-726
pubmed: 34157090
Br J Surg. 2016 May;103(6):656-667
pubmed: 26990957
Ann Surg. 2007 Jun;245(6):886-92
pubmed: 17522514
PLoS One. 2019 Jul 25;14(7):e0220202
pubmed: 31344073